investorscraft@gmail.com

Intrinsic Value of Akebia Therapeutics, Inc. (AKBA)

Previous Close$3.62
Intrinsic Value
Upside potential
Previous Close
$3.62

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney diseases. The company’s primary product, Auryxia (ferric citrate), is an FDA-approved treatment for hyperphosphatemia in chronic kidney disease patients on dialysis and iron deficiency anemia in non-dialysis-dependent CKD patients. Akebia operates in the highly competitive nephrology sector, where it competes with larger pharmaceutical firms by leveraging its specialized expertise in renal care. The company’s revenue model relies on product sales and strategic partnerships, including collaborations with Vifor Pharma and other regional distributors to expand market reach. Despite its niche focus, Akebia faces challenges from generic competition and pricing pressures, which impact its ability to scale profitability. Its market position is further shaped by ongoing R&D efforts, including pipeline candidates targeting unmet needs in kidney disease, though commercialization risks remain significant given the capital-intensive nature of biopharma.

Revenue Profitability And Efficiency

Akebia reported revenue of $160.2 million for FY 2024, reflecting its reliance on Auryxia sales. However, the company posted a net loss of $69.4 million, with diluted EPS of -$0.33, indicating persistent profitability challenges. Operating cash flow was negative at $40.7 million, while capital expenditures were minimal ($33,000), suggesting constrained investment capacity. These metrics underscore inefficiencies in converting revenue to sustainable earnings.

Earnings Power And Capital Efficiency

The company’s negative earnings and cash flow highlight limited earnings power, driven by high R&D and commercialization costs relative to revenue. Capital efficiency remains weak, as evidenced by the inability to generate positive free cash flow. With no dividends and reliance on external funding, Akebia’s ability to self-finance growth is constrained, necessitating careful liquidity management.

Balance Sheet And Financial Health

Akebia’s balance sheet shows $51.9 million in cash and equivalents against $47.6 million in total debt, yielding a modest net cash position. However, recurring losses and negative cash flows raise concerns about long-term solvency. The absence of dividend payouts aligns with its focus on preserving liquidity for operations and pipeline development.

Growth Trends And Dividend Policy

Growth is contingent on Auryxia’s commercial traction and pipeline advancements, though revenue growth has not yet translated to profitability. The company does not pay dividends, prioritizing reinvestment in R&D and debt management. Investor returns are likely tied to speculative pipeline milestones rather than current cash generation.

Valuation And Market Expectations

The market likely prices Akebia based on its pipeline potential rather than near-term fundamentals. Negative earnings and cash flows suggest a high-risk profile, with valuation hinging on clinical successes or partnership deals. The stock’s performance may remain volatile pending material catalysts.

Strategic Advantages And Outlook

Akebia’s focus on kidney disease provides a differentiated niche, but its outlook depends on overcoming commercialization hurdles and pipeline progress. Strategic partnerships and cost discipline could improve its trajectory, though competition and funding needs pose ongoing risks. The company’s ability to achieve profitability remains uncertain without significant revenue scaling or pipeline wins.

Sources

Company filings (10-K), investor presentations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount